Kuehn Law, PLLC is investigating whether certain officers and directors of Picard Medical Inc. breached their fiduciary duties to shareholders amid allegations of a fraudulent stock promotion scheme. The law firm's inquiry centers on claims that insiders caused the company to misrepresent or fail to disclose material information regarding artificial trading activity and the use of offshore accounts to facilitate share dumping. These alleged actions are significant as they may have artificially inflated the stock price, impacting the investment decisions of shareholders.

According to a federal securities lawsuit cited by Kuehn Law, Picard Medical was the subject of a scheme involving social media-based misinformation and impersonated financial professionals. The lawsuit alleges that insiders and affiliates utilized offshore or nominee accounts to coordinate the dumping of shares during a price inflation campaign. Furthermore, it is claimed that Picard Medical's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price.

The investigation focuses on the period leading up to September 2, 2025. Shareholders who currently own Picard Medical stock and purchased shares prior to this date are advised to contact Justin Kuehn, Esq. to discuss their rights. Kuehn Law has stated that it pays all case costs and does not charge its investor clients for participation in the matter.

Kuehn Law emphasizes that shareholder participation is crucial for maintaining the integrity and fairness of the financial markets. The firm has noted that there may be limited time for shareholders to enforce their rights regarding these allegations.